Immunohistochemistry Market Size
|2019 - 2029
|Base Year For Estimation
|Fastest Growing Market
*Disclaimer: Major Players sorted in no particular order
Need a report that reflects how COVID-19 has impacted this market and its growth?
Immunohistochemistry Market Analysis
The immunohistochemistry market is projected to grow at a CAGR of nearly 7.3% over the forecast period.
The SARS-CoV-2 outbreak significantly impacted the market's growth during the initial phase since laboratories, and research institutes faced shortages of reagent supply due to the global lockdown. For instance, as per the ASCP February 2022 update, during the pandemic, the need for specimen tubes and other common laboratory consumables threatened access to all aspects of diagnostic testing. As several research organizations and biopharmaceutical companies evaluated immunofluorescence assay to develop it as an effective diagnostic tool for COVID-19, the reagent shortages hugely impacted the market growth. Moreover, SARS-CoV-2 can also be detected by IHC using a dsRNA antibody. In the post-pandemic situation, the market is expected to rise in the coming years due to the rising utilization of immunohistochemistry in the diagnosis of various chronic diseases.
The major factor contributing to the market's growth is the increase in cancer incidence, as immunohistochemistry is used to diagnose cancer and other diseases including antigen-antibody reactions. For instance, according to the American Cancer Society 2023 Cancer Statistics, it is estimated that about 1.96 million new cases of cancer would be diagnosed in the United States in 2023, as compared to 1.89 million in 2021. Hence, with the increasing burden of cancer and awareness about it, the demand for early diagnostics is expected to increase, thereby boosting growth in the market.
Also, the technological advancements in immunohistochemistry products are likely to improve the efficiency and effectiveness of existing products which is anticipated to have a positive impact on the demand for immunohistochemistry products over the forecast period. For instance, in July 2022, NextCure published a paper that utilized a newly developed antibody to Siglec-15 (S15) and an immunohistochemical (IHC) assay to investigate S15 expression in solid tumors. The publication outlines data from a study conducted in collaboration with researchers in the Department of Pathology at Yale School of Medicine.
Moreover, the rapidly increasing geriatric population and high burden of chronic & infectious diseases are further expected to drive the demand for IHC products for diagnostics and testing applications over the forecast period. For instance, as per a United Nations 2022 report, the global geriatric population is increasing rapidly and the share of the global population aged 65 years or above is projected to rise from 10% in 2022 to 16% in 2050. Since the geriatric population is more prone to chronic diseases, a corresponding rise is likely to increase the utilization of tests and thereby lead to market growth.
However, limited reimbursement policies and the high cost of IHC products are anticipated to restrain the market growth.
Immunohistochemistry Market Trends
This section covers the major market trends shaping the Immunohistochemistry Market according to our research experts:
The Diagnostics Segment is Expected to Hold a Significant Share in the Immunohistochemistry Market Over the Forecast Period
Major factors contributing to the growth of the diagnostic segment are new product launches by several market players, increasing point-of-care diagnostics, and rapidly evolving technology. Furthermore, viral epidemics and chronic diseases worldwide and the use of diagnostic techniques to develop and subsequently administer personalized medicine are likely to boost market growth. For instance, as per the January 2023 update by CDC, 85.1 thousand cases of monkeypox are diagnosed globally.
The large share of this segment is credited to the growing predominance of various chronic diseases and the wide application of immunohistochemistry in the diagnosis of infectious diseases, cardiovascular diseases, and other diseases. For instance, as per an article published in February 2022 in PubMed, a study indicated that immunostaining of vimentin as a marker for myocardial remodeling and the dynamics of all non-myocardial cell types might be useful for supplementing conventional staining techniques currently used in the diagnosis of ischemic heart disease. Ischemic heart disease and stroke are the predominant causes and are responsible for more than 80% of CVD fatalities.
As per an article published in August 2022 in JACC, the United States National Health and Nutrition Examination Survey found that stroke (33.8% to 15 million) and heart failure (33.4% to 13 million) have the highest projected increases in cardiovascular disease rates, followed by ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million) for the projected years 2025 to 2060. Hence, applications to diagnose heart disease using immunostaining are expected to increase the demand for IHC products.
In addition, new product launches, strategic activities like collaborations, mergers, and acquisitions by the key players, and an increase in research activities are further expected to add to the segment's growth. For instance, in June 2021, Amoy Diagnostics Co. Ltd, Riken Genesis Co. Ltd, and Precision Medicine Asia Co. Ltd introduced the AmoyDx Pan Lung Cancer PCR Panel in the market. The panel was approved by the Ministry of Health, Labour, and Welfare (MHLW) for marketing and production in Japan. Similarly, in January 2021, Thermo Fisher Scientific acquired Mesa Biotech, a privately held molecular diagnostic company. Mesa Biotech's innovative platform will enable the company to accelerate the availability of reliable and accurate advanced molecular diagnostics at point-of-care.
North America is Anticipated to Hold a Significant Market Share in the Market Over the Forecast Period
North America is expected to hold a notable market share throughout the forecast period due to the factors such as the presence of key players, the high prevalence of cancer and other chronic diseases in the region, and the established healthcare infrastructure. For instance, as stated by the American Heart Association 2021 journal, it is estimated that by the year 2035, more than 130 million adults in the United States will have some type of heart disease. Similarly, as per the Statistics Canada 2022 update, an estimated 233.9 thousand people in Canada are expected to be diagnosed with cancer. The growing demand for effective diagnostic solutions to obtain proper treatment for heart disease and cancer is expected to drive the growth of the market in North America.
In addition, as per Canada's population estimates for 2022, almost one in five Canadians (18.8% of the population; 7,329,910 people) were at least 65 years of age. Hence, the prevalence of chronic diseases coupled with the increasing geriatric population in the country is anticipated to create more opportunities for the development of immunochemistry tools during the forecast period.
Furthermore, an increase in new product launches relating to the market studied boosts the growth of the market. For instance, in December 2021, BioGenex, an automated staining solution provider for cancer diagnostics launched three new primary immunohistochemistry (IHC) antibodies for cancer diagnosis. Furthermore, in March 2021, Roche launched the DISCOVERY Green HRP chromogen detection kit to expand immunohistochemistry multiplexing in cancer research.
Immunohistochemistry Industry Overview
The immunohistochemistry market is highly competitive and consists of several major players. Some of the key companies in the market are F. Hoffmann-LA Roche, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Merck Millipore, Abcam PLC, Bio-Rad Laboratories, Inc., PerkinElmer, Inc., Cell Signaling Technology, Inc., and Bio SB.
Immunohistochemistry Market Leaders
F. Hoffmann-LA Roche AG
Thermo Fisher Scientific Inc.
Agilent Technologies, Inc.
*Disclaimer: Major Players sorted in no particular order
Immunohistochemistry Market News
- In September 2022, Roche launched the Anti-PRAME (EPR 20330) Rabbit Monoclonal Primary Antibody to identify PRAME protein expression in tissue samples from patients with suspected melanoma.
- In March 2022, Boston Cell Standards launched the Consortium for Analytic Standardization in Immunohistochemistry (CASI) with the goal of improving patient immunohistochemistry (IHC) test accuracy and reproducibility. The consortium is led by an international panel of pathologists and scientists and is being funded by an initial USD 2 million grant from the U.S. National Cancer Institute.
Immunohistochemistry Market Report - Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Cancer
4.2.2 Rapidly Increasing Geriatric Population and High Burden of Chronic & Infectious Diseases
4.2.3 Technological Advancement in IHC and Growing Biological Research
4.3 Market Restraints
4.3.1 High Cost IHC Products
4.3.2 Lack of Proper Reimbursement Policies
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size - Value in USD million)
5.1 By Product
5.1.3 Kits and Reagents
5.2 By Application
5.2.2 Drug Testing
5.3 By End-User
5.3.1 Hospitals and Diagnostics Centers
5.3.2 Academic & Research Institutes
5.3.3 Other End-users
5.4.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.4.4 Middle East and Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle East and Africa
5.4.5 South America
184.108.40.206 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 F. Hoffmann-LA Roche AG
6.1.2 Agilent Technologies, Inc.
6.1.3 Thermo Fisher Scientific Inc.
6.1.4 Merck KGaA
6.1.5 Abcam PLC
6.1.6 Bio-Rad Laboratories, Inc.
6.1.7 PerkinElmer, Inc.
6.1.8 Cell Signaling Technology, Inc.
6.1.9 Bio SB
6.1.10 Danaher Corporation
6.1.11 Takara Bio
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Immunohistochemistry Market Research FAQs
What is the current Global Immunohistochemistry Market size?
The Global Immunohistochemistry Market is projected to register a CAGR of 7.30% during the forecast period (2024-2029)
Who are the key players in Global Immunohistochemistry Market?
F. Hoffmann-LA Roche AG, Thermo Fisher Scientific Inc., Merck KGaA, Abcam PLC and Agilent Technologies, Inc. are the major companies operating in the Global Immunohistochemistry Market.
Which is the fastest growing region in Global Immunohistochemistry Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Immunohistochemistry Market?
In 2024, the North America accounts for the largest market share in Global Immunohistochemistry Market.
What years does this Global Immunohistochemistry Market cover?
The report covers the Global Immunohistochemistry Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Immunohistochemistry Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
IHC Industry Report
Statistics for the 2024 IHC market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. IHC analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.